フィルターを表示する
リソースの種類
フィルターで絞り込む リソースの種類
Pathologies
フィルターで絞り込む Pathologies
Technologies
フィルターで絞り込む Technologies
Instruments
フィルターで絞り込む Instruments
10 検索結果
並び替え:

Sebia acquires Zeus Scientific

プレスリリース
10月. 12, 2022

The strategic acquisition reinforces Sebia’s product portfolio & strategy in autoimmunity

Performance of Immunotyping vs. Immunofixation for the Detection of Monoclonal Gammopathies

ウェビナー
9月. 30, 2022

Educational Webinar with Katie Thoren, PhD, Memorial Sloan Kettering Cancer Center

Sebia and Metafora biosystems form strategic partnership to develop advanced in vitro diagnostics

プレスリリース
9月. 30, 2022

Sebia to acquire a minority stake in Metafora biosystems.

Multiple Myeloma clinical cases for diagnosis and monitoring according to latest IMWG recommendations

ウェビナー
9月. 30, 2022

Educational Webinar with Prof. Alessandro Gozzetti, MD, PhD

Experience and recommendations of a Major Cancer Center to use HYDRASHIFT daratumumab

出版物
9月. 30, 2022

Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.

Sebia Acquires Orgentec Diagnostika

プレスリリース
9月. 30, 2022

The strategic acquisition reinforces Sebia’s global leadership in specialty diagnostics.

Discover how the automation track integration boosted the high potential of CAPILLARYS 3

お客様の声
9月. 30, 2022

With this short video report, become aware of all the benefits of partnering with Sebia and integrate your capillary electrophoresis into the lab track automation.